Odevixibat

Odevixibat
Clinical data
Trade namesBylvay
Other namesA4250
AHFS/Drugs.comMonograph
MedlinePlusa621049
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
  • (2S)-2-{[(2R)-2-[({[3,3-Dibutyl-7-(methylsulfanyl)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC37H48N4O8S2
Molar mass740.93 g·mol−1
3D model (JSmol)
  • CCCCC1(CCCC)CN(C2=CC=CC=C2)C2=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C3=CC=C(O)C=C3)C=C2S(=O)(=O)N1
  • InChI=1S/C37H48N4O8S2/c1-5-8-19-37(20-9-6-2)24-41(26-13-11-10-12-14-26)29-21-31(50-4)30(22-32(29)51(47,48)40-37)49-23-33(43)39-34(25-15-17-27(42)18-16-25)35(44)38-28(7-3)36(45)46/h10-18,21-22,28,34,40,42H,5-9,19-20,23-24H2,1-4H3,(H,38,44)(H,39,43)(H,45,46)/t28-,34+/m0/s1
  • Key:XULSCZPZVQIMFM-IPZQJPLYSA-N

Odevixibat, sold under the brand name Bylvay among others, is a medication for the treatment of progressive familial intrahepatic cholestasis.[5][9] It is taken by mouth.[5] Odevixibat is a reversible, potent, selective inhibitor of the ileal bile acid transporter (IBAT).[9][10][11] It was developed by Albireo Pharma.[12]

The most common side effects include diarrhea, abdominal pain, hemorrhagic diarrhea, soft feces, and hepatomegaly (enlarged liver).[9]

Odevixibat was approved for medical use in the United States and in the European Union in July 2021.[5][6][7][13][14] The U.S. Food and Drug Administration considers it to be a first-in-class medication.[15]

Medical uses

In the United States, odevixibat is indicated for the treatment of pruritus in people three months of age and older with progressive familial intrahepatic cholestasis.[5] In the European Union it is indicated in people six months of age and older.[6][7]

Mechanism of action

Odevixibat is a reversible inhibitor of the ileal sodium/bile acid co-transporter. This transporter is responsible for reabsorption of the majority of bile acids in the distal ileum.[16] The reduced absorption of the bile acids in the distal ileum compounds and leads to a decrease in stimulation of FXR (farnesoid X receptor), decreasing the inhibition of bile acid synthesis.[17]

Odevixibat works as a reversible, selective, small molecule inhibitor of the ileal bile acid transporter (IBAT).[9][11]

Pharmacokinetics

Odevixibat is > 99% protein-bound in vitro.[17] A dose of odevixibat that is 7.2 mg reaches a cmax concentration of 0.47 ng/mL with an AUC (0-24h) of 2.19 h*ng/mL.[17] Adult and pediatric patients given the therapeautic dose of odevixibat did not display plasma concentrations of the drug.[14] Odevixibat is eliminated majorly unchanged.[17] Odevixibat has an average half-life of 2.36 hours.[17]

The peak plasma time ranges from 1 to 5 hours after a single 7.2 mg dose in healthy adults. In healthy adults receiving a single 7.2 mg dose, the peak plasma concentration is 0.47 ng/mL, and the area under the concentration-time curve (AUC) is 2.19 ng·hr/mL. The plasma concentration of odevixibat in patients aged 6 months to 17 years ranges from 0.06 to 0.72 ng/mL. With once-daily dosing, there is no accumulation of odevixibat.[18]

Odevixibat is metabolized through a process called mono-hydroxylation.The drug is primarily eliminated through the feces (97% unchanged), with a minimal amount excreted in the urine (0.002%).[19]

Consuming a high-fat meal (800-1000 calories with approximately 50% of the total caloric content from fat) the peak plasma concentration is decreased by 72%, the AUC by 62%, and delays the peak plasma time by 3 to 4.5 hours. However, the impact of food on systemic exposures to odevixibat is not clinically significant.[20]

Contraindications

Odevixibat cannot be given to a child on a liquid diet.[17]

Adverse effects

Common side effects of odevixibat include diarrhea, stomach pain, vomiting, liver test abnormalities, abnormal liquid function tests, and a deficiency in vitamins A, D, E and K.[21][17]

Pregnancy and lactation

There are no enough human data on odevixibat use during pregnancy to build a drug-associated risk of major birth defects, miscarriage, or adverse developmental outcomes.[21]

There are no data on the presence of odevixibat in human milk, and how it affects milk production and breastfed babies.[21]

History

Preclinical studies and early clinical trials were conducted to evaluate the safety and efficacy of odevixibat, to establish the appropriate dosage, assess its mechanism of action, and evaluate its effects on bile acid levels and symptoms in people with progressive familial intrahepatic cholestasis. A 24-week clinical trial, played a role in demonstrating the effectiveness and safety of odevixibat in treating pruritus in children with progressive familial intrahepatic cholestasis.[19]

The US Food and Drug Administration (FDA) granted the application for odevixibat orphan drug designation.[15] The FDA classified odevixibat as an orphan drug for the rare conditions of Alagille syndrome, biliary atresia, and primary biliary cholangitis.[21]

Odevixibat was granted its initial approval in July 2021, in the European Union for the treatment of progressive familial intrahepatic cholestasis in people aged six months and older. In July 2021, it received approval in the United States for the treatment of pruritus (itching) in people aged three months and older with progressive familial intrahepatic cholestasis.[22]

Society and culture

In May 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended granting a marketing authorization in the European Union for odevixibat for the treatment of progressive familial intrahepatic cholestasis in people aged six months or older.[9][23] It was authorized for medical use in the European Union in July 2021.[6][7]

In July 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Kayfanda, intended for the treatment of cholestatic pruritus in people with Alagille syndrome aged six months or older.[8][24] The applicant for this medicinal product is Ipsen Pharma.[8] Kayfanda was authorized for medical use in the European Union in September 2024.[8]

Research

A phase III randomized control trial showed odevixibat reduced pruritis and serum bile acids in children with progressive familial intrahepatic cholestasis.[25]

References

  1. ^ "Details for: Bylvay". Health Canada. 30 October 2023. Retrieved 3 March 2024.
  2. ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2023-12-22]". Health Canada. 22 December 2023. Retrieved 3 January 2024.
  3. ^ "Regulatory Decision Summary for Bylvay". Drug and Health Products Portal. 23 October 2023. Retrieved 2 April 2024.
  4. ^ "Summary Basis of Decision for Bylvay". Drug and Health Products Portal. 1 September 2012. Retrieved 9 May 2024.
  5. ^ a b c d e "Bylvay- odevixibat capsule, coated pellets". DailyMed. U.S. National Library of Medicine. Archived from the original on 29 July 2021. Retrieved 28 July 2021.
  6. ^ a b c d "Bylvay EPAR". European Medicines Agency (EMA). 20 April 2021. Archived from the original on 29 July 2021. Retrieved 28 July 2021.
  7. ^ a b c d "Bylvay". Union Register of medicinal products. Archived from the original on 24 July 2021. Retrieved 23 July 2021.
  8. ^ a b c d "Kayfanda EPAR". European Medicines Agency (EMA). 25 July 2024. Retrieved 25 July 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  9. ^ a b c d e "First treatment for rare liver disease". European Medicines Agency (EMA) (Press release). 21 May 2021. Retrieved 21 May 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  10. ^ "Odevixibat". Albireo Pharma. Archived from the original on 22 May 2021. Retrieved 21 May 2021.
  11. ^ a b Karpen SJ, Kelly D, Mack C, Stein P (September 2020). "Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders". Hepatology International. 14 (5): 677–689. doi:10.1007/s12072-020-10070-w. PMID 32653991. S2CID 220481607.
  12. ^ Deeks ED (October 2021). "Odevixibat: First Approval". Drugs. 81 (15): 1781–1786. doi:10.1007/s40265-021-01594-y. PMC 8550539. PMID 34499340.
  13. ^ "Odevixibat: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 27 September 2021. Retrieved 23 July 2021.
  14. ^ a b "Albireo Announces FDA Approval of Bylvay (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)". Albireo Pharma (Press release). 20 July 2021. Retrieved 23 July 2021 – via GlobeNewswire.
  15. ^ a b Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. Public Domain This article incorporates text from this source, which is in the public domain.
  16. ^ "Odevixibat". go.drugbank.com. Archived from the original on 19 September 2021. Retrieved 13 June 2022.
  17. ^ a b c d e f g "Odevixibat Monograph for Professionals". Drugs.com. 30 August 2022. Archived from the original on 15 December 2022. Retrieved 6 July 2023.
  18. ^ Yu S, Wang D, Yu J, Yin Y, Xie S, Cheng Q, et al. (May 2021). "Plasma or serum, which is the better choice for the measurement of metanephrines?". Scandinavian Journal of Clinical and Laboratory Investigation. 81 (3): 250–253. doi:10.1080/00365513.2021.1904280. PMID 33787416. S2CID 232430232. Archived from the original on 7 July 2023. Retrieved 7 July 2023.
  19. ^ a b Ray K (September 2022). "Positive phase III results for odevixibat for progressive familial intrahepatic cholestasis". Nature Reviews. Gastroenterology & Hepatology. 19 (9): 556. doi:10.1038/s41575-022-00667-x. PMID 35879356. S2CID 251021808.
  20. ^ Taylor L, Gidal B, Blakey G, Tayo B, Morrison G (November 2018). "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects". CNS Drugs. 32 (11): 1053–1067. doi:10.1007/s40263-018-0578-5. PMC 6223703. PMID 30374683. Archived from the original on 7 July 2023. Retrieved 7 July 2023.
  21. ^ a b c d Porwal M, Kumar A, Rastogi V, Maheshwari KK, Verma A (March 2023). "Odevixibat: A Review of a Bioactive Compound for the Treatment of Pruritus Approved by the FDA". Current Drug Research Reviews. 15: 32–42. doi:10.2174/2589977515666230308125238. PMID 36892028. S2CID 257426837.
  22. ^ Deeks ED (October 2021). "Odevixibat: First Approval". Drugs. 81 (15): 1781–1786. doi:10.1007/s40265-021-01594-y. PMC 8550539. PMID 34499340. Archived from the original on 7 July 2023. Retrieved 7 July 2023.
  23. ^ "Bylvay: Pending EC decision". European Medicines Agency (EMA). 19 May 2021. Archived from the original on 21 May 2021. Retrieved 21 May 2021.
  24. ^ "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024". European Medicines Agency (EMA) (Press release). 25 July 2024. Retrieved 29 July 2024.
  25. ^ Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, et al. (September 2022). "Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial". The Lancet. Gastroenterology & Hepatology. 7 (9): 830–842. doi:10.1016/S2468-1253(22)00093-0. PMID 35780807. S2CID 250229742.
  • Clinical trial number NCT03566238 for "This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC 1 or 2 (PEDFIC 1)" at ClinicalTrials.gov

Read other articles:

Alexander Winton

Artikel ini perlu diwikifikasi agar memenuhi standar kualitas Wikipedia. Anda dapat memberikan bantuan berupa penambahan pranala dalam, atau dengan merapikan tata letak dari artikel ini. Untuk keterangan lebih lanjut, klik [tampil] di bagian kanan. Mengganti markah HTML dengan markah wiki bila dimungkinkan. Tambahkan pranala wiki. Bila dirasa perlu, buatlah pautan ke artikel wiki lainnya dengan cara menambahkan [[ dan ]] pada kata yang bersangkutan (lihat WP:LINK untuk keterangan lebih lanjut...

 

 

Bible study (Christianity)

Study of the Bible Bible reading redirects here. For reading in church, see Lection. For the academic field, see biblical studies. Part of a series on theBible Canons and books Tanakh Torah Nevi'im Ketuvim Old Testament (OT) New Testament (NT) Deuterocanon Antilegomena Chapters and verses Apocrypha Jewish OT NT Authorship and development Authorship Dating Hebrew canon Old Testament canon New Testament canon Composition of the Torah Mosaic authorship Pauline epistles Petrine epistles Johannine...

 

 

Media in Pittsburgh

Mass media in Pittsburgh Pittsburgh is home to the first commercial radio station in the United States, KDKA 1020AM, the first community-sponsored television station in the United States, WQED 13, the first networked television station and the first station in the country to broadcast 24 hours a day, 7 days a week, KDKA 2, and the first newspaper published west of the Allegheny Mountains, the Pittsburgh Post-Gazette. History Until 2016, Pittsburgh was one of the few mid-sized metropolitan are...

مجتمع المساواة

يفتقر محتوى هذه المقالة إلى الاستشهاد بمصادر. فضلاً، ساهم في تطوير هذه المقالة من خلال إضافة مصادر موثوق بها. أي معلومات غير موثقة يمكن التشكيك بها وإزالتها. (مارس 2016) مجتمعات المساواة هي مجموعات الأشخاص الذين اختاروا الحياة معًا، بحيث تكون المساواة واحدة من القيم الرئيسية...

 

 

1995 in spaceflight

Spaceflight-related events of 1995 1995 in spaceflightSpace Shuttle Atlantis launches on STS-71, the first Shuttle-Mir mission to dock with MirOrbital launchesFirst11 JanuaryLast24 DecemberTotal80Successes72Failures5Partial failures3Catalogued74National firstsSatellite Czech Republic (post Czechoslovakian) Ukraine (post Soviet)RocketsMaiden flightsAthena IConestogaDelta II 7920Long March 1DVolnaShavit 1RetirementsAtlas E/FConestogaLong March 2EMu-3SIISoyuz-U2Crewed flightsOrbital9To...

 

 

Peringatan Partai Komunis Tiongkok ke-100

Peringatan Partai Komunis Tiongkok ke-100Bagian dari Dua CentenariLogo resmi acara tersebut, ditampilkan di Distrik Tianxin, Changsha, Hunan, Tiongkok.Nama asli 中国共产党成立100周年庆祝活动Tanggal01 Juli 2021 (2021-07-01)LokasiJalan Chang'an, Lapangan Tiananmen, Beijing, TiongkokKoordinat39°54′26.4″N 116°23′27.9″E / 39.907333°N 116.391083°E / 39.907333; 116.391083Koordinat: 39°54′26.4″N 116°23′27.9″E / 39.90...

Sungai Asahan

Sungai AsahanAek TobaAek AsahanSei AsahanSebuah jembatan yang melintang di daerah hulu sungai Asahan sekitar Porsea, Toba (1929).LokasiNegaraIndonesiaProvinsiSumatera UtaraCiri-ciri fisikHulu sungaiDanau Toba - elevasi950 m (3.120 ft) Muara sungaiSelat Malaka - lokasiBagan Asahan - koordinat3°01′53″N 99°51′47″E / 3.03133°N 99.86306°E / 3.03133; 99.86306Koordinat: 3°01′53″N 99°51′47″E / 3.0313...

 

 

Apple A16

System on a chip (SoC) designed by Apple Inc. Apple A16 BionicGeneral informationLaunchedSeptember 7, 2022Marketed byApple Inc.Designed byApple Inc.Common manufacturer(s)TSMCProduct codeAPL1W10[1]PerformanceMax. CPU clock rate2020 MHz to 3460 MHzCacheL2 cache16 MB (performance cores) 4 MB (efficient cores)Last level cache24 MBArchitecture and classificationApplicationMobileTechnology node4 nm N4PMicroarchitectureEverestSawtoothInstructionsARMv8.6-APhysica...

 

 

Ziad Jaziri

Ziad Jaziri Nazionalità  Tunisia Altezza 171 cm Calcio Ruolo Attaccante Termine carriera 2008 Carriera Squadre di club1 1999-2003 Étoile du Sahel87 (47)2003-2005 Gaziantepspor49 (17)2005-2007 Troyes44 (6)2007-2008 Kuwait SC20 (8) Nazionale 1999-2008 Tunisia64 (14) Palmarès  Coppa d'Africa Oro Tunisia 2004 1 I due numeri indicano le presenze e le reti segnate, per le sole partite di campionato.Il simbolo → indica un trasferimento in prestito.   Modifica...

The Secret Storm

American television soap opera (1954–1974) This section is about the American soap opera. For the musical act Lauren Hoffman & the Secret Storm, see Lauren Hoffman. The Secret StormTitle card for The Secret Storm, 1954Created byRoy WinsorStarringPeter HobbsJada RowlandMarla AdamsCountry of originUnited StatesNo. of seasons20No. of episodes5,195ProductionRunning time15 minutes (1954–1962, approx. 11–12 minutes minus ads)30 minutes (1962–1974, approx. 22 minutes minus ads)Original r...

 

 

Iconography of St. Louis

The St. Louis flag features two rivers merging in a confluence of French heritage signified by a fleur-de-lis. The Iconography of St. Louis, Missouri is strongly informed by the city's French and German heritages, physical features, and place in American history. Mound City Monks Mound is one of the few remaining mounds in the St. Louis region. Long before Europeans settled in St. Louis, the Cahokia lived throughout the area and constructed many mounds. Though history and population growth wo...

 

 

格奥尔基·季米特洛夫

此條目之中立性有争议。其內容、語調可能帶有明顯的個人觀點或地方色彩。 (2011年6月)加上此模板的編輯者需在討論頁說明此文中立性有爭議的原因，以便讓各編輯者討論和改善。在編輯之前請務必察看讨论页。 格奥尔基·季米特洛夫保加利亚共产党中央委员会总书记任期1948年8月—1949年7月2日前任自己（第一书记）继任维尔科·契尔文科夫保加利亚共产党中央委员会第一�...

Simbolo atanasiano

Un libro in antico slavo ecclesiastico mostra il simbolo atanasiano. Černihiv, Museo. Il simbolo atanasiano (Quicumque vult) è un simbolo della fede che prende questo nome perché attribuito dalla tradizione cristiana al vescovo Atanasio di Alessandria (295-373). È significativo soprattutto per la dottrina trinitaria, che esso esprime in maniera forte per combattere l'arianesimo. Nella liturgia della Chiesa occidentale era recitato nell'ufficio divino domenicale di prima.[1] Nel ri...

 

 

Gyros

Greek dish This article is about the Greek dish. For the moth genus, see Gyros (moth). For other uses, see Gyro (disambiguation). GyrosGyros in Greece, with meat, onions, tomato, lettuce, fried potatoes, and tzatziki rolled in a pitaAlternative namesGyro[1]TypeMeat wrapCourseMain coursePlace of originGreeceServing temperatureHotMain ingredientsMeat: pork, chicken, beef, or lamb  Media: Gyros Gyros, sometimes anglicized as a gyro[2][3][4] (/ˈjɪəroʊ,...

 

 

Guts (flying disc game)

Game involving throwing flying discs at the opposing team Guts or disc guts (sometimes guts Frisbee in reference to the trademarked brand name) is a disc game inspired by dodgeball, involving teams throwing a flying disc (rather than balls) at members of the opposing team. Game play One to five team members stand in a line facing the opposing team across the court, with the two teams lined up parallel to each other. Which team begins play is determined by flipping the disc, an action similar ...

Politecnico di Milano

Politecnico di Milano La sede di Milano Leonardo UbicazioneStato Italia CittàMilano Altre sediComo, Cremona, Lecco, Mantova, Piacenza Dati generaliSoprannomePoliMI Fondazione29 novembre 1863 FondatoreFrancesco Brioschi TipoPolitecnico statale ScuoleArchitettura Urbanistica Ingegneria delle Costruzioni (AUIC), Design (DESIGN), ingegneria industriale e dell'informazione (3I), Ingegneria Civile Ambientale e Territoriale (ICAT) Dipartimenti12 RettoreDonatella Sciuto[3] Dir. ge...

 

 

20 січня

← січень → Пн Вт Ср Чт Пт Сб Нд 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31         2024 рік 20 січня — 20-й день року в григоріанському календарі. До кінця року залишається 345 днів (346 днів — у високосні роки), собор св. Йоана Хрестителя. Цей день в історії: 19 с...

 

 

ويكيبيديا اللوكسمبورغية

ويكيبيديا اللكسمبورغيةالشعارمعلومات عامةموقع الويب lb.wikipedia.org (اللوكسمبورغية) تجاري؟ لانوع الموقع موسوعة حرةالتأسيس 21 يوليو 2004 الجوانب التقنيةاللغة اللكسمبورغيةترخيص المحتوى رخصة المشاع الإبداعي الملزِمة بالنسب لمؤلِّف العمل وبالترخيص بالمثل غير القابلة للإلغاء 3.0 — �...

TVB星河頻道電視劇集列表 (2019年)

建議将此條目或章節併入TVB星河頻道重播電視劇列表。（討論） 此條目没有列出任何参考或来源。 (2019年1月1日)維基百科所有的內容都應該可供查證。请协助補充可靠来源以改善这篇条目。无法查证的內容可能會因為異議提出而被移除。 本列表列出香港TVB星河頻道重播的劇集。 首映年份 電視劇集名稱 集數 2012年翡翠台劇集 愛·回家_(第一輯)Come Home Love 804 首映年份 電視劇�...

 

 

Kubok Ukraïny 2010-2011

Kubok Ukraïny 2010-2011Кубок України Competizione Kubok Ukraïny Sport Calcio Edizione 20ª Date dal 27 luglio 2010al 25 maggio 2011 Luogo  Ucraina Partecipanti 53 Risultati Vincitore Šachtar(7º titolo) Secondo Dinamo Kiev Semi-finalisti Arsenal KievDnipro Statistiche Miglior marcatore Andriy Oliynyk (5) Incontri disputati 51 Gol segnati 139 (2,73 per incontro) Lo Shakhtar vincitore della manifestazione Cronologia della competizione 2009-2010 2011-2012 M...